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Background: The relationship between resistin and non-alcoholic steatohepatitis (NASH) is not clear, some studies
claimed that serum resistin levels were associated with neither the presence of NASH nor its severity, others declared
that serum resistin was related with inflammation and fibrosis in NASH. Our animal study verified that the distribution
of resistin in the liver is correlated with inflammation in NASH. However, there is no pertinent study in humans.
Methods: Thirty patients with NASH, 28 simple steatosis, and 43 controls were recruited. Blood was collected for
resistin, liver chemistries, fasting insulin and some metabolic parameters. Liver histology was scored according to
NAFLD activity scoring system. Hepatic resistin expression was examined by real-time polymerase chain reaction,
immunohistochemistry. Resistin protein expression was confirmed by western blotting in 13 patients with concomitant
NAFLD and gallstone.
Results: Serum resistin was significantly elevated in both NASH and simple steatotic subjects compared with controls
(all P < 0.05). Hepatic resistin was significantly increased in NASH patients in both mRNA and protein levels than those
in simple steatosis and control subjects (all P < 0.05). Both serum and hepatic resistin had a correlation with obesity, but
not with insulin resistance. The distribution of resistin positive cells was predominantly in perisinusoidal cells (such as
Kupffer cells and hepatic stellate cells) in human NASH. Multivariate analysis revealed that waist-hip ratio, higher serum
triglyceride, and hyperresistinemia were independent factors related to higher grade of steatosis; whereas hepatic
resistin and serum cytokeratin predict NASH and severity of liver fibrosis.
Conclusions: Hepatic resistin overexpression in NASH patients is associated with the severity of liver inflammation
and fibrosis. Liver-derived resistin may be involved in the pathogenesis of human NASH.
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Nonalcoholic fatty liver disease (NAFLD) is a clinico-
pathological entity with a wide spectrum ranging from
simple steatosis, to steatohepatitis (NASH), to cirrhosis
[1,2]. Being different to the past views, fatty liver is now
regarded as an abnormal condition due to simple steato-
sis patients also exhibiting elevated liver enzymes in
serum. However, it is widely accepted that NASH is the
more aggressive form of NAFLD, which is characterized* Correspondence: zhaocy2005@163.com
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unless otherwise stated.by the hepatocellular injury, hepatic infiltration of in-
flammatory cells. Strong evidence suggests that NASH
ultimately lead to scarring of the liver (fibrosis) and then
irreversible, advanced scarring (cirrhosis) [3]. The mech-
anism of NASH is still not clear, proinflammatory cyto-
kines, such as tumor necrosis factor α (TNF-α) and
interferon γ are involved. Recent studies found that
resistin is another important cytokine to be implicated
in the pathogenesis of NASH.
Resistin, also known as found in inflammatory zone-3
(FIZZ-3), is a cysteine-rich polypeptide primarily pro-
duced by white adipose tissue in rodents and monocytes
or macrophages in humans [4]. Several rodent modelsd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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liver [5,6]. However, the physiological role of resistin in
humans remains controversial. Some studies claimed
that serum resistin levels were associated neither with
presence of NASH nor with its severity [7,8], others de-
clared that serum resistin was related with inflammation,
fibrosis and its severity in NASH [9,10]. Although resistin
is recognized as a proinflammatory cytokine, the role of
its local expression in the liver is not clear. Our animal
study showed that resistin has direct effects on NASH:
(1) resistin was increased in inflammatory liver in rats;
and (2) recombinant resistin directly stimulate activation
of nuclear factor kappa B and proinflammatory cytokines
secretion in murine hepatocytes [11]. There is no relevant
data available in human being. To verify the connection
between resistin and NASH in human may eventually lead
to NASH intervention.
The present study was to evaluate the circulating and
hepatic resistin expression in patients with biopsy-proven
NASH and those with simple steatosis, and to assess the
associations of resistin expression with metabolic profiles
and inflammation in human liver.
Methods
Study design
We prospectively studied 58 biopsy-proven NAFLD
patients (30 with NASH and 28 with simple steatosis) at
the Third Affiliated Hospital of Hebei Medical University
between July 2008 and October 2010. NAFLD was diag-
nosed by ultrasound, alanine aminotransferase (ALT) and
biopsy, the diagnostic criteria was the guidelines for the
diagnosis and treatment of NAFLD suggested by the
Chinese National Consensus Workshop on Nonalcoholic
Fatty Liver Disease [12]. Exclusion criteria were as follows:
a history of excessive alcohol consumption (>140 g/wk for
male and >70 g/wk for female), viral hepatitis (hepatitis B
and C), alcoholic liver disease, autoimmune hepatitis,
primary biliary cirrhosis, primary sclerosing cholangitis,
Wilson’s disease, hemochromatosis, α-1 antitrypsin defi-
ciency, biliary obstruction, secondary causes of steatosis,
and drug-induced liver disease. Forty-three healthy blood
donor volunteers matched for age and sex were recruited
as controls: normal liver function, no signs of fatty liver on
ultrasound and negative serology for viral hepatitis. Seven
liver samples from patients with cavernous hemangioma
were also involved in this study. None of the participants
had history of primary hypertension, cardiovascular dis-
ease, malignancy, hypo- or hyperthyroidism and the use of
thiazolidinediones. Previously diagnosed type 2 diabetes
patients were also excluded from this cohort.
Written informed consent was obtained from all partici-
pants prior to enrollment. And the study protocol was
reviewed and approved by the Ethics Committee of the
Third Affiliated Hospital of Hebei Medical University.Clinical and biochemical evaluations
Anthropometric parameters including weight, height,
waist circumference, and hip circumference were mea-
sured. Body mass index (BMI) was calculated as the body
weight (kg) divided by the square of the height (m).
Waist-hip ratio (WHR) was calculated as the waist cir-
cumference (cm) divided by the hip circumference (cm).
A venous blood sample for determination of ALT, as-
partate aminotransferase (AST), γ-glutamyl transferase
(GGT), glucose, triglyceride (TG), total cholesterol (TC),
high-density lipoprotein cholesterol (HDL-C) and low-
density lipoprotein cholesterol (LDL-C) was collected in
each participant following a 12-hour overnight fasting.
Serum insulin was determined by a radioimmunoassay
technique. The homeostasis model assessment of insulin
resistance (HOMA-IR) score was calculated as the product
of fasting glucose (mmol/L) and fasting insulin (μIU/mL)
divided by 22.5.
Liver tissue collection
Percutaneous liver biopsies were performed in 58
NAFLD patients. A sample was considered valid for
the study if it was at least 1.5 cm in length. Since in-
sufficient amount of liver tissues by percutaneous liver
biopsies, a few representative liver tissues for western
blotting were also obtained in 13 patients with NAFLD
(5 with NASH and 8 with simple steatosis) during
laparoscopic cholecystectomy due to gallstone. For fur-
ther comparison, seven samples of relatively normal liver
tissue were collected from patients with cavernous
hemangioma of the liver during surgical hepatectomy.
One third of each specimen was immediately stored in
RNA fixer (GENEray Biotechnology, Shanghai, China) and
then stored at −80°C until RNA or protein extraction. The
remains were fixed in 10% formalin for histology and
immunohistochemistry.
Hepatopathological analysis
The biopsies containing at least six portal tracts were
considered appropriate for evaluation. The specimens were
stained with hematoxylin-eosin and Masson trichrome.
Histology was reviewed by a single hepatopathologist
who was blind to the clinical data. The histological
scoring of NAFLD followed the NAFLD Activity Score
(NAS) proposed by The Pathological Committee of the
NASH Clinical Research Network [13]. The score was
composed of steatosis (0 = <5%, 1 = 5% − 33%, 2 = 34% −
66%, 3 = >66%), lobular inflammation (0 = no foci, 1 = <2
foci per 200 × field, 2 = 2–4 foci per 200 × field, 3 = >4
foci per 200 × field), and ballooning (0 = none, 1 = rare
or few, 2 =many or prominent). Fibrosis staging was re-
corded as following criteria: 0 = none, 1 = perisinusoidal or
periportal fibrosis, 2 = perisinusoidal and portal/periportal
fibrosis, 3 = bridging fibrosis, and 4 = cirrhosis. The score
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“borderline”, and simple steatosis, respectively. The
“borderline” patients with NAS 3 or 4 were also identified
as NASH under further investigation by original Brunt cri-
teria [14] (i.e. steatosis together with ballooning and/or
Mallory-Denk bodies or fibrosis ≥ 2), while the remainder
were regarded as simple steatosis.
Real-time polymerase chain reaction (PCR)
Total RNA was extracted from the RNA fixer-stored
specimen using Trizol reagent (Invitrogen, Carlsbad, CA)
according to the protocol. The extracted RNA was reverse
transcribed to first strand cDNA using the PrimeScript RT
reagent Kit (Fermentas, Burlington, ON, Canada). Quanti-
fication of the gene expressions were carried out in a
thermal cycler (ABI 7500; Applied Biosystems, Foster City,
CA) using a SYBR-green RealMaster Mix kit (TianGen
Biotech, Beijing, China). The PCR parameters were an ini-
tial denaturation at 94°C for 5 min; followed by 30 cycles
(94°C for 45 s, 56°C for 45 s, and 72°C for 1 min).
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was
used as an internal control. The sequences of oligonucleo-
tide primers for PCR included: resistin: forward: 5′-CCA
TGG AAG AAG CCA TCA AT-3′and reverse: 5′-CTG
GCA GTG ACA TGT GGT CT-3′ (product size: 209 bp);
and GAPDH: forward: 5′-ACC ACA GTC CAT GCC
ATC ACT-3′ and reverse: 5′-TCC ACC ACC CTG TTG
CTG TA-3′ (product size: 452 bp). For each sample, PCR
was performed twice in triplicates, and all data were ana-
lyzed by the thermal cycler’s software to calculate the △Ct
value (△Ct = Ct value of the target gene minus Ct value of
the internal control gene). The level of resistin mRNA in
healthy controls was assigned as a reference value of 1.
Relative expression of resistin to the internal control was
calculated using a 2-△△Ct method [15].
Western blotting
Liver tissues were lysed in RIPA lysis buffer with prote-
ase inhibitors according to manufacturer’s instructions
(BestBio, China). The concentration of protein was mea-
sured by the Bradford method. Equal amounts of pro-
teins (100 μg) were loaded onto 5% condensed gel and
12% SDS-PAGE gel for electrophoresis, followed by
western blotting onto polyvinylidene difluoride mem-
branes by semi-dry transfer method (Hoefer TE70X
Semi-dry Bloters, USA). The membranes were blocked
with 1×TBST containing 5% nonfat milk, and then incu-
bated with both anti-resistin monoclonal antibody
(1:2000; Epitomics) and anti-β-actin monoclonal anti-
body (1:800; Santa Cruz Biotechnology) overnight at
4°C. After washing three times, the blots were detected
with Odyssey infrared imaging system (LI-COR, USA).
The levels of protein were calculated as the ratio of the in-
tensity of resistin to that of β-actin.Immunohistochemistry
Five μm paraffin-embedded liver sections were digested
with trypsinase for 30 min at 37°C, followed by the anti-
gen retrieval via pressure cooking for 2 min in 0.01 mol/
L citrate buffer (PH 6.0). After blocking the activity of
endogenous peroxidase with 3% methanol-H2O2, all sec-
tions were incubated with monoclonal antibody against
human resistin (1:100 dilution; R&D Systems, USA)
overnight at 4°C. After washing with 0.01 mol/L
phosphate-buffered saline (PBS) (PH 7.2), Two-Step IHC
Detection Reagent (Zhongshan Golden Bridge Biotech,
Beijing, China) containing secondary rabbit anti-mouse
antibody, and 3, 3′-Diaminobenzidine tetrahydrochloride
Substrate Kit (Zhongshan Golden Bridge Biotech,
Beijing, China) were applied according to the manufac-
turer’s protocols. The slides incubated with PBS instead
of primary antibody were used as negative controls. All
sections were counterstained with hematoxylin following
immunochemical staining. Semi-quantitative (SQ) ana-
lysis of the average density of resistin expression was
performed using a CMIAS-II morphometric analysor
(Beijing University of Aeronautics and Aerospace,
China). The average density was calculated by positive
staining areas/total areas × 100% in a 400× high-power
field (hpf ) [16].Serum resistin and cytokeratin-18 (CK-18) levels by
enzyme-linked immunosorbent assays (ELISA)
Serum levels of resistin and CK-18 fragment were mea-
sured by ELISA using commercially available kits (resis-
tin: Rapidbio, West Hills, CA, USA; CK-18: PEVIVA,
Alexis, Grunwald, Germany) according to the manufac-
turer’s instructions. All serum samples were analyzed in
duplicates.Statistical analyses
All analyses were performed by SPSS version 13.0
(Chicago, IL, USA). All statistical tests were two-tailed, and
P < 0.05 was considered to be statistically significant.
Continuous variables were expressed as means ±
standard deviation (SD). Differences between groups
were analyzed by One-Way ANOVA, followed by
Student-Newman-Keuls test for multiple comparisons.
Logarithmic transformation of data was performed when
appropriate. Pearson Chi-square test or Fisher’s exact
test were used to analyze categorical variables. Bivariate
correlation analysis was assessed by Pearson correlation
test or Spearman correlation test.
Logistic regression analysis with forward stepwise vari-
ables selection was used to demonstrate the independent
predictors for the histological severity of steatosis,
necroinflammation, and fibrosis. The covariates included
age, gender, BMI, WHR, ALT, TG, HOMA-IR score,
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of hepatic resistin expression.
Results
Characteristics of patients and controls
The anthropometric and biochemical data are presented
in Table 1. The BMI was significantly higher in the
NASH patients than that in the simple steatosis subjects
(P < 0.05), and the BMI in almost all of the NASH
patients (28/30) was greater than 25; whereas no signifi-
cant differences in WHR (P = 0.88) were observed be-
tween NASH and simple steatosis. In this cohort, ALT,
AST, GGT, glucose, insulin, HOMA-IR, TG, and LDL-C
were significantly increased in both NASH and simple
steatosis. Both ALT and serum CK-18 fragment level
were significantly higher in NASH patients than that in
patients with simple steatosis (P < 0.05). In contrast,
HLD-C was significantly decreased in both NASH and
simple steatosis compared with control group (P < 0.05).
There was no significant differences in serum TC among
the three groups (P = 0.12).
Liver histology
The histological findings were summarized in Table 2.
Of all NAFLD patients, thirty (52%) were histologically
diagnosed as NASH. Among NASH patients, eighteen
(60%) had moderate-to-severe (grade 2 or 3) steatosis;
14 (47%) had mild (grade 1) lobular inflammatory, 16Table 1 Anthropometric and biochemical characteristics of al
NASH
(n = 30)
Age (year) 42 ± 9
Sex (male/female) 19/11
Body weight (kg) 80.5 ± 10.2a,b
BMI (kg/m2) 28.2 ± 1.9a,b
Waist circumference (cm) 101 ± 10b
WHR 0.95 ± 0.04b
ALT (U/L) 82 ± 14a,b
AST (U/L) 38 ± 9b
GGT (U/L) 86 ± 14b
Fasting glucose (mmol/L) 6.1 ± 0.6b
Fasting insulin (μIU/mL) 10.9 ± 2.2b
HOMA-IR score 2.9 ± 0.6b
Triglyceride (mmol/L) 2.22 ± 0.62b
Total cholesterol (mmol/L) 5.32 ± 0.75
HDL-C (mmol/L) 1.21 ± 0.23b
LDL-C (mmol/L) 3.26 ± 0.52b
CK-18 (U/L) 391.89 ± 123.68a,b
Results were expressed as mean ± SD.
aP < 0.05 vs. simple steatosis group; bP < 0.05 vs. Controls.(53%) moderate-to-severe (grade 2 or 3); 17 (57%) had
mild ballooning, 13 (43%) had many balloon cells; 18
(60%) had none or mild fibrosis (stage 0 or 1), 12 (40%)
in stage 2 or 3. Steatosis was the most prominent histo-
logical change in simple steatosis and it was milder com-
pared with patients with NASH.
Increased circulating resistin concentration in NAFLD
patients
Serum resistin concentration in patients with NAFLD
was significantly higher than that in controls (6.30 ± 1.54
vs. 3.14 ± 1.22 ng/mL, P < 0.05), while there was no sig-
nificant difference in the subtypes of NAFLD patients
(Figure 1A). Gender is not a factor to affect serum resis-
tin in each group. Serum resistin level in NAFLD patients
had a positive correlation with WHR (r = 0.41, P = 0.001),
ALT (r = 0.31, P = 0.02), GGT (r = 0.35, P = 0.007), TG
(r = 0.34, P = 0.01), CK-18 fragment level (r = 0.64, P = 0.02)
and histological grade of steatosis (rho = 0.43, P = 0.001)
(Figure 1B). There was no correlation between serum resis-
tin and HOMA-IR score (P = 0.14).
Up-regulation of resistin in liver of NASH patients
Hepatic resistin mRNA expression was significantly up-
regulated in NASH patients compared with simple stea-
tosis group (P < 0.05) and controls (P < 0.05) (Figure 2A).
In parallel, NASH patients exhibited increased resistin
protein expression detected by SQ-analysis than those inl studied subjects
Simple steatosis Controls P value
(n = 28) (n = 43)
44 ± 12 45 ± 14 0.64
19/9 29/14 0.92
74.8 ± 10.1 62.1 ± 7.9 <0.001
26.6 ± 2.6 22.0 ± 1.8 <0.001
99 ± 10 84 ± 7 <0.001
0.94 ± 0.05 0.87 ± 0.05 <0.001
68 ± 13 21 ± 9 <0.001
35 ± 8 18 ± 6 <0.001
80 ± 15 28 ± 10 <0.001
5.9 ± 0.5 4.9 ± 0.4 <0.001
10.2 ± 2.5 7.4 ± 2.3 <0.001
2.6 ± 0.7 1.6 ± 0.5 <0.001
2.04 ± 0.51 1.13 ± 0.44 <0.001
5.19 ± 0.72 4.99 ± 0.57 0.12
1.12 ± 0.26 1.33 ± 0.18 0.01
3.23 ± 0.69 2.55 ± 0.47 <0.001
277.87 ± 109.90 163.62 ± 73.52 <0.001
Table 2 Histological studies of patients with NASH and
simple steatosis
NASH Simple steatosis
(n = 30) (n = 28)
Steatosis grade
0 0 (0%) 0 (0%)
1 12 (40%) 16 (57%)
2 14 (47%) 9 (32%)
3 4 (13%) 3 (11%)
Lobular inflammation grade
0 0 (0%) 28 (100%)
1 14 (47%) 0 (0%)
2 13 (43%) 0 (0%)
3 3 (10%) 0 (0%)
Hepatocyte ballooning grade
0 0 (0%) 28 (100%)
1 17 (57%) 0 (0%)
2 13 (43%) 0 (0%)
Fibrosis stage
0 6 (20%) 20 (71%)
1 12 (40%) 8 (29%)
2 9 (30%) 0 (0%)
3 3 (10%) 0 (0%)
4 0 (0%) 0 (0%)
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hpf, P < 0.05) and controls (vs. 0.30% ± 0.09% per hpf,
P < 0.05). These SQ-analysis results of resistin protein
expression were in agreement with the western blotting re-
sults from a small proportion of patients with co-existence
of both NASH and gallstone, patients with concomitant
simple steatosis and gallstone, and controls (Figure 2B).
Nevertheless, resistin was scarcely expressed in livers of
healthy controls.Figure 1 Serum resistin level was the highest in patients with NASH (
NAFLD cohort (B).Localization of resistin in liver tissue
Immunohistochemistry showed that resistin positive
cells were predominantly distributed in hepatic perisinu-
soidal area (Figure 3), occasionally in portal tracts.
Predictors for the histological severity of steatosis,
necroinflammation, and fibrosis
In this entire NAFLD cohort, hepatic resistin protein ex-
pression by SQ analysis was positively correlated with
BMI (r = 0.38, P = 0.003) and ALT (r = 0.48, P < 0.001).
Furthermore, it had a positive correlation with histo-
logical lobular inflammation grade (rho = 0.56, P = 0.002)
(Figure 4A), hepatocyte ballooning (rho = 0.68, P < 0.001)
(Figure 4B), and fibrosis stage (rho = 0.62, P = 0.001)
(Figure 4C). However, there was no correlation with
HOMA-IR (r = 0.22, P = 0.09). On logistic regression ana-
lysis, WHR (odds ratio [OR] 3.5; 95% confidence interval
[CI] 1.4-9.2; P = 0.009), TG (OR 2.4; 95% CI 1.0-5.7;
P = 0.045), and hyperresistinemia (OR 2.1; 95% CI 1.0-4.5;
P = 0.045) can be used to predict moderate-to-severe hep-
atic steatosis. Furthermore, both serum CK-18 fragment
level and amount of resistin positive cells in the liver were
independent factors either to predict NASH presence
(CK-18: OR 6.4; 95% CI 1.1-7.5; P = 0.002 and resistin: OR
4.3; 95% CI 1.9-14.3; P = 0.004) or moderate-to-severe liver
fibrosis (CK-18: OR 5.3; 95% CI 1.6-9.2; P = 0.003 and
resistin: OR 3.6; 95% CI 1.1-12.5; P = 0.012).
Discussion
In the present study, we found that (1) resistin was sig-
nificantly increased in the liver of NASH patients com-
pared with that of subjects with simple steatosis and
controls; (2) resistin distribution and its density is closely
correlated with the inflammation and inflammatory se-
verity in the liver; (3) both serum and hepatic resistin ex-
pression had correlation with obesity, but not with
insulin resistance; (4) immunoreactivity for resistin was
confined to hepatic perisinusoidal cells; and (5) WHR,A), and correlated with histological steatosis grade in the whole
Figure 2 Patients with NASH exhibit increased hepatic resistin expression in mRNA (A) and ptotein levels (B) than patients with simple
steatosis, and controls.
Shen et al. BMC Gastroenterology 2014, 14:39 Page 6 of 8
http://www.biomedcentral.com/1471-230X/14/39hypertriglyceridemia, and hyperresistinemia were the in-
dependent predictors for the higher degree of steatosis,
whereas increased serum CK-18 and hepatic resistin
levels predicted NASH and more severe histological
fibrosis.
The link between resistin and NAFLD remains under
debate in humans. It is accepted that obesity, particularly
central obesity is a risk factor strongly associated with
NAFLD [17-19]. About half of the literatures support
the notion that serum resistin increases are accountable
for the obesity and insulin resistance [20-23], while the
other half showed the opposite: resistin is downregulated
in obese subjects and resistin had no correlation with in-
sulin resistance [8,10,24]. Resistin is primarily secreted
by monocytes or macrophages in humans [25-27]. On
one hand, obesity-associated inflammation stimulates
the adipocytes themselves to produce inflammatory me-
diators, on the other hand, these inflammation media-
tors aggravate inflammation and thus, increases resistin
secretion and vice versa. This vicious circle causes and
maintains macrophages infiltration into adipose tissue
[28,29]. Our data showed that, in NAFLD patients,Figure 3 Immunohistochemistry for resistin in human liver tissue. Rep
patients with NASH (A), patients with simple steatosis (B), and controls (C)serum resistin correlated with WHR, and hepatic resis-
tin protein expression correlated with BMI, whether this
correlation is coincidence or casual-effect needs further
investigation.
Accumulating evidence indicates that resistin has pro-
inflammatory properties. Resistin enhances interleukin 6
and TNF-α production, both are increased in NAFLD
patients [7,30-32]. Our results showed that resistin was
increased in liver of NASH patients, and there was a
positive correlation between resistin and inflammatory
severity in the liver of NASH patients. The distribution
and density of resistin positive cells was associated with
the existence and severity of necroinflammation, bal-
looning, and fibrosis, these results are consistent with
other studies [10,33]. Moreover, recent studies have
demonstrated that several useful biomarkers, such as
CK-18 and fetuin-A, may reflect apoptosis, necrosis of
hepatocytes, as well as disease severity in NAFLD [34,35].
In this NAFLD cohort, there is a positive correlation
between serum resistin and CK-18, which is largely in-
creased in NASH patients. Thus, our and other studies
might implicate that resistin had direct effect on liverresentative expression and distribution of resistin in liver tissues of
, respectively. (Original magnification: 400× for A and B; 200× for C).
Figure 4 Spearman correlation analysis demonstrates that hepatic resistin protein expression correlates with lobular inflammation (A),
hepatocyte ballooning (B), and fibrosis stage (C) in patients with NAFLD.
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of liver tissue obtained by percutaneous liver biopsy,
quantitative analysis of hepatic resistin protein content
has only been performed in a small number of NAFLD
patients together with gall stones who are willing to
provide liver tissues during laparoscopic cholecystec-
tomy. Thus, quantitative liver resisitin protein content
needs to be examined in a further larger cohort.
Another interesting finding is that serum resistin had
positive correlation with hepatic fat content in NAFLD
patients. Furthermore, WHR, increased serum TG, and
hyperresistinemia predicted moderate-to-severe steato-
sis. The excess resistin found in the serum of NAFLD
patients among other molecules that might metabolically
be important could contribute to the speed-up of meta-
bolic deterioration observed in NAFLD [4]. The serum
resistin in NASH patients is similar with that in the sub-
jects with simple steatosis, while resistin content in
NASH liver is significantly higher than that in the liver
of simple steatosis. This inconsistency might indicate
that serum resistin is parallel with fat accumulation in
the body, liver is one of the organs where the fat is
stored. Although the serum resistin level is almost the
same in NAFLD, the ALT and CK-18 are significantly in-
creased in NASH patients compared with simple steato-
sis which means that it is the resistin in the liver that
may initiate the progression from simple steatosis to
NASH and it is the resistin in the liver that correlated
with inflammation and fibrosis and, damage the liver tis-
sue to release biomarkers of liver injury.
We further identified the cell types in liver responsible
for the production of resistin by immunohistochemistry.
Our findings showed that resistin protein expression was
mainly localized in perisinusoidal cells. It is proposed
that the liver harbors two types of cells that are par-
ticularly attractive candidates for resistin production—
Kupffer cells (i.e. resident liver macrophages) and hepatic
stem cells (HSC) (i.e. adipocyte-like cells), which exert theirphysiological actions in a paracrine or autocrine way. Our
hypothesis was partially supported by another independent
study, which demonstrated that the presence of resistin ap-
peared in Kupffer cells, in a subset of endothelial cells, and
occasionally in fibroblast-like cells [36]. Previously it was
also suggested that hepatocyte could produce resistin [33],
but the results from Szalowska’s group [36] and our group
could not confirm this observation.
Conclusions
In summary, the present study suggests that resistin is
overexpressed in liver of patients with NASH, resistin
correlates with the severity of liver necroinflammation
and fibrosis. Hepatic resistin may be primarily produced
by perisinusoidal cells (such as Kupffer cells and HSCs) in
human NASH. As no specific receptors for resistin have
been identified, the precise cellular or molecular mechan-
ism of resistin contributing to NAFLD development and
its disease progression needs further investigations.
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